Global heparin market to grow by $3.34b by 2028

Key developments include fractionated and low-molecular-weight heparin for thrombosis management.

The global heparin market is projected to rise by $3.34b by 2028 at an annual growth rate of 7.22%, said Technavio.

The sector’s expansion is attributed to the rising prevalence of blood clotting disorders and venous thromboembolism, including deep vein thrombosis and pulmonary embolism.

Heparin, a widely used anticoagulant, prevents blood clots in veins and arteries. Both animal-derived unfractionated heparin and plasma-derived therapies are commonly used.

“Major advancements include fractionated heparin and low-molecular-weight heparin, expanding thrombosis management options,” the report said.

However, side effects, fungal infections, counterfeit drugs, and the rising prevalence of chronic diseases like diabetes, cancer, and cardiovascular disease hinder market growth.